Financial Daily from THE HINDU group of publications
Tuesday, Nov 23, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements
Marketing - New Products & Services
Industry & Economy - Health


Ranbaxy launches new drug for urological disorder

Our Bureau

New Delhi , Nov. 22

RANBAXY Laboratories Ltd today announced the launch of its benign prostatic hyperplasia (BPH) formulation, branded Flotral (Alfuzosin). It is being launched for the first time in the Indian market.

This prescription medicine provides effective relief from signs and symptoms of BPH, a urological disorder, caused due to the enlargement of the prostate gland and commonly afflicts the ageing male population.

Flotral, is a once-a-day medication, developed using the Novel Drug Delivery System (NDDS) technology platform, resulting in better patient compliance.

Mr Sanjeev I. Dani, Regional Director - India, said in a statement, "The launch of Flotral further expands Ranbaxy's key strategic product portfolio and establishes the company's commitment to build its urology franchise through its competitive edge technology of NDDS."

Meanwhile, the pharmaceutical company is planning to restructure its business by exiting from its non-core segments such as animal healthcare, diagnostics and fine chemicals.

These account for close to Rs 125 crore of the company's turnover.

When contacted Ranbaxy officials "refused to comment on market rumours".

According to an analyst tracking the company, "The decision to hive off the non-core business will enable the company to focus on its core pharmaceuticals business. Except for the Fine Chemicals business, the company may be of the view that there are no synergies with the other business, though these segments may demand dedicated resources."

More Stories on : Announcements | New Products & Services | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Mukesh clarifies on `ownership issues'


Ranbaxy launches new drug for urological disorder
Deccan Chronicle plans launch in TN by Feb `05
ABB to invest $100 m in India
Reliance keen on bringing gas to Bengal from K-G find
BHEL bags Rs 26-cr orders
ICAI disclosure norms for court-ordered accounts
Ford India sales income up 29 pc; net loss pared
To fund capacity expansion — Bajaj Hind mulls Rs 100-cr equity infusion
Talks on Bajarang Jute mill reopening
Deccan Gold signs exploration pact with De Beers
DS Group plans jt venture with Lotte for confectionery biz
Motherson Sumi to set up second venture with Woco
Eicher eyes Rs 2,000-cr turnover this fiscal
MPI to invest Rs 10 cr to double capacity
The meeting that never was
Rupee options a hit among corporates



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line